If a patient has a two‑month gap between doses of Emgality (galcanezumab), should they repeat the 240 mg loading dose?

No Loading Dose Required After a 2-Month Gap

If a patient misses 2 months between Emgality doses, they should simply resume with the standard 120 mg maintenance dose—no loading dose is necessary. 1

FDA-Approved Dosing Guidance

The FDA prescribing information for Emgality explicitly addresses missed doses: "If a dose of EMGALITY is missed, administer as soon as possible. Thereafter, EMGALITY can be scheduled monthly from the date of the last dose." 1 This guidance makes no distinction based on the duration of the gap and does not recommend repeating the 240 mg loading dose regardless of how much time has elapsed.

Pharmacokinetic Rationale

Emgality has favorable pharmacokinetic properties that support this approach:

• Half-life of 27 days 1
• Time to steady-state: A 240 mg loading dose achieves steady-state after the first dose, while 120 mg monthly dosing reaches steady-state after the fourth dose 1
• After 2 months (approximately 60 days), this represents roughly 2.2 half-lives—meaning some drug remains in circulation

The loading dose strategy is designed to rapidly achieve therapeutic levels at treatment initiation. Once a patient has been on therapy, even after a 2-month gap, they are not starting from zero drug exposure.

Extrapolation from Biologic Guidelines

While the evidence provided includes guidelines for other biologics (psoriasis treatments), these offer relevant context. The AAD-NPF guidelines suggest considering repeating loading doses "if the patient is flaring and/or if more than 3-4 half-lives have passed since the previous dose" 2.

For Emgality:

• 3-4 half-lives = 81-108 days (approximately 3-3.5 months)
• A 2-month gap falls below this threshold
• Migraine is not a "flaring" condition in the same way as psoriasis—it's a chronic preventive indication

Clinical Evidence Supporting Continuation

Studies demonstrate that galcanezumab maintains efficacy with standard monthly dosing:

• The REGAIN study showed sustained reduction in migraine headache days over 3 months with monthly 120 mg dosing 3
• Long-term safety studies confirmed efficacy over 12 months with consistent monthly dosing 4
• No evidence suggests that brief interruptions require dose escalation

Practical Algorithm

For a 2-month gap in Emgality dosing:

1. Resume immediately with 120 mg subcutaneous injection
2. Schedule subsequent doses monthly from this restart date
3. Monitor response over the next 2-3 months
4. If inadequate response after resuming (not achieving meaningful reduction in migraine days), consider whether the patient was a responder initially—this would guide whether to continue therapy, not whether to reload

Important Caveats

• The FDA label does not specify a maximum gap duration that would necessitate reloading
• Unlike some biologics where immunogenicity concerns drive reloading decisions, galcanezumab's IgG4 structure has low immunogenic potential 1
• Patient adherence counseling is critical—emphasize the importance of maintaining monthly dosing for optimal preventive efficacy
• If the patient had poor initial response or never achieved benefit, the issue is likely non-response rather than need for reloading

Bottom line: Simply restart with 120 mg and continue monthly dosing. The loading dose is a one-time strategy for treatment initiation, not for brief treatment interruptions.